Correction: Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis [Mol Cell Biol, 35, 6, (2015) (988-1000)] DOI: 10.1128/MCB.01242-14;Role of MicroRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis

Molecular and Cellular Biology

Volumn 35, Issue 6, 2015, Pages 988-1000

  Zhang, Qian ^a,b   Tang, Qingchao ^a,b   Qin, Dandan ^a   Yu, Lei ^a,b   Huang, Rui ^a,b   Lv, Guixiang ^b   Zou, Zhaoxia ^b   Jiang, Xiao chen ^b   Zou, Chendan ^b   Liu, Wei ^b   Luo, Jing ^b   Zhao, Zhixun ^a,b   Muhammad, Shan ^a,b   Wang, Guiyu ^a,b   Chen, Ying gang ^a,b   Wang, Xishan ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 2; MICRORNA; MICRORNA 30A; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, HUMAN;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; CANCER CELL LINE; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CANCER TISSUE; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CELL TRANSFORMATION; COLORECTAL TUMOR; GENETICS; HCT116 CELL LINE; NUDE MOUSE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENES, TUMOR SUPPRESSOR; HCT116 CELLS; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84923205463     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00246-17     Document Type: Erratum

References (52)

1. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics. CA Cancer J Clin 63:11-30. http://dx.doi.org/10.3322/caac.21166.
2. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297. http://dx.doi.org/10.1016/S0092-8674(04)00045-5.
3. Alvarez-Garcia I, Miska EA. 2005. MicroRNA functions in animal development and human disease. Development 132:4653-4662. http://dx.doi.org/10.1242/dev.02073.
4. Ambros V. 2004. The functions of animal microRNAs. Nature 431:350-355. http://dx.doi.org/10.1038/nature02871.
5. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D, Lowenstein CJ. 2010. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A 107:6334-6339. http://dx.doi.org/10.1073/pnas.0911082107.
6. Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, Condorelli G, Banfi S, Verde P. 2014. miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene 0 (25 August 2014). http://dx.doi.org/10.1038/onc.2014.267.
7. Chan SH, Huang WC, Chang JW, Chang KJ, Kuo WH, Wang MY, Lin KY, Uen YH, Hou MF, Lin CM, Jang TH, Tu CW, Lee YR, Lee YH, Tien MT, Wang LH. 2014. MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis. Oncogene 33:4496-4507. http://dx.doi.org/10.1038/onc.2014.10.
8. Wang Y, Tang Q, Li M, Jiang S, Wang X. 2014. MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. Biochem Biophys Res Commun 444:199-204. http://dx.doi.org/10.1016/j.bbrc.2014.01.028.
9. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT. 2008. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40:43-50. http://dx.doi.org/10.1038/ng.2007.30.
10. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M, Allgayer H. 2012. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 130:2044-2053. http://dx.doi.org/10.1002/ijc.26218.
11. Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, Shen CY. 2012. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res Treat 134:1081-1093. http://dx.doi.org/10.1007/s10549-012-2034-4.
12. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A. 2007. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26:7590-7595. http://dx.doi.org/10.1038/sj.onc.1210564.
13. Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. 2010. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 59:579-585. http://dx.doi.org/10.1136/gut.2008.175497.
14. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. 2004. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 101:11755-11760. http://dx.doi.org/10.1073/pnas.0404432101.
15. Tian D, Zhang W, He J, Liu Y, Song Z, Zhou Z, Zheng M, Hu Y. 2012. Novel, real-time cell analysis for measuring viral cytopathogenesis and the efficacy of neutralizing antibodies to the 2009 influenza A (H1N1) virus. PLoS One 7:e31965. http://dx.doi.org/10.1371/journal.pone.0031965.
16. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S, Sahin O. 2012. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actinregulatory proteins FHOD1 and PPM1F. Mol Cell Biol 32:633-651. http://dx.doi.org/10.1128/MCB.06212-11.
17. Madhunapantula SV, Robertson GP. 2011. Therapeutic implications of targetingAKTsignaling in melanoma. Enzyme Res 2011:327923. http://dx.doi.org/10.4061/2011/327923.
18. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A, Raponi M. 2009. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9:374. http://dx.doi.org/10.1186/1471-2407-9-374.
19. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM, Subramanian S, Wang L, Smyrk TC, Rodrigues CM, Thibodeau SN, Steer CJ. 2009. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9:401. http://dx.doi.org/10.1186/1471-2407-9-401.
20. Monzo M, Navarro A, Bandres E, Artells R, Moreno I, Gel B, Ibeas R, Moreno J, Martinez F, Diaz T, Martinez A, Balague O, Garcia-Foncillas J. 2008. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 18:823-833. http://dx.doi.org/10.1038/cr.2008.81.
21. Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X, Liu CG, Yang JM. 2009. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy 5:816-823. http://dx.doi.org/10.4161/auto.9064.
22. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zollner H, Munding J, Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W, Hahn SA. 2012. MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 33:732-739. http://dx.doi.org/10.1093/carcin/bgs020.
23. Zhong M, Bian Z, Wu Z. 2013. miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. Cell Physiol Biochem 31:209-218. http://dx.doi.org/10.1159/000343362.
24. Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, Hu G, Yang Q. 2014. MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene 33:3119-3128. http://dx.doi.org/10.1038/onc.2013.286.
25. Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G, Fiore D, De Marinis P, Croce CM, Condorelli G. 2013. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene 32:4001-4008. http://dx.doi.org/10.1038/onc.2012.410.
26. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. 2012. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18:74-82. http://dx.doi.org/10.1038/nm.2577.
27. Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, Shimizu K. 2012. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One 7:e31422. http://dx.doi.org/10.1371/journal.pone.0031422.
28. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW. 2008. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47:897-907. http://dx.doi.org/10.1002/hep.22160.
29. Yao J, Liang L, Huang S, Ding J, Tan N, Zhao Y, Yan M, Ge C, Zhang Z, Chen T, Wan D, Yao M, Li J, Gu J, He X. 2010. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology 51:846-856. http://dx.doi.org/10.1002/hep.23443.
30. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N, Shao Y, Darvishian F, Zavadil J, Erlebacher A, Mahal LK, Osman I, Hernando E. 2011. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 20:104-118. http://dx.doi.org/10.1016/j.ccr.2011.05.027.
31. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H. 2010. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28:1721-1726. http://dx.doi.org/10.1200/JCO.2009.24.9342.
32. Li N, Kaur S, Greshock J, Lassus H, Zhong X, Wang Y, Leminen A, Shao Z, Hu X, Liang S, Katsaros D, Huang Q, Butzow R, Weber BL, Coukos G, Zhang L. 2012. A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res 72:154-164. http://dx.doi.org/10.1158/0008-5472.CAN-11-2484.
33. Wu F, Zhu S, Ding Y, Beck WT, Mo YY. 2009. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 15:1550-1557. http://dx.doi.org/10.1158/1078-0432.CCR-08-0820.
34. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J. 2012. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 13:633-641. http://dx.doi.org/10.1016/S1470-2045(12)70102-X.
35. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG, Jr, Glasheen E, Lane WS, Pierce JH, White MF. 1995. Role of IRS-2 in insulin and cytokine signalling. Nature 377:173-177.
36. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF. 1991. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352:73-77.
37. Bjornholm M, He AR, Attersand A, Lake S, Liu SC, Lienhard GE, Taylor S, Arner P, Zierath JR. 2002. Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans. Diabetologia 45:1697-1702. http://dx.doi.org/10.1007/s00125-002-0945-z.
38. Lavan BE, Lane WS, Lienhard GE. 1997. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem 272:11439-11443.
39. Day E, Poulogiannis G, McCaughan F, Mulholland S, Arends MJ, Ibrahim AE, Dear PH. 2013. IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. Int J Exp Pathol 94:203-211. http://dx.doi.org/10.1111/iep.12021.
40. Gibson SL, Ma Z, Shaw LM. 2007. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 6:631-637. http://dx.doi.org/10.4161/cc.6.6.3987.
41. Kornmann M, Maruyama H, Bergmann U, Tangvoranuntakul P, Beger HG, White MF, Korc M. 1998. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res 58:4250-4254.
42. Boissan M, Beurel E, Wendum D, Rey C, Lecluse Y, Housset C, Lacombe ML, Desbois-Mouthon C. 2005. Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 167:869-877. http://dx.doi.org/10.1016/S0002-9440(10)62058-5.
43. Lips EH, de Graaf EJ, Tollenaar RA, van Eijk R, Oosting J, Szuhai K, Karsten T, Nanya Y, Ogawa S, van de Velde CJ, Eilers PH, van Wezel T, Morreau H. 2007. Single nucleotide polymorphism array analysis of chromosomal instability patterns discriminates rectal adenomas from carcinomas. J Pathol 212:269-277. http://dx.doi.org/10.1002/path.2180.
44. Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC, Protopopov A, Ivanova E, Brennan C, Montgomery K, Kucherlapati R, Bailey G, Redston M, Chin L, DePinho RA. 2007. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res 67:10736-10743. http://dx.doi.org/10.1158/0008-5472.CAN-07-2742.
45. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. 2008. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14:6364-6370. http://dx.doi.org/10.1158/1078-0432.CCR-07-4879.
46. Liang J, Slingerland JM. 2003. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339-345. http://dx.doi.org/10.4161/cc.2.4.433.
47. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. 2006. MicroRNA expression and function in cancer. Trends Mol Med 12:580-587. http://dx.doi.org/10.1016/j.molmed.2006.10.006.
48. Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, Giraud AS. 2014. Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One 9:e95993. http://dx.doi.org/10.1371/journal.pone.0095993.
49. Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK, Lin J. 2001. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20:7925-7934. http://dx.doi.org/10.1038/sj.onc.1204990.
50. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. 2003. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63:1270-1279.
51. Hsu YL, Hou MF, Kuo PL, Huang YF, Tsai EM. 2013. Breast tumorassociated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/snail signaling pathway. Oncogene 32:4436-4447. http://dx.doi.org/10.1038/onc.2012.444.
52. Gao L, Wang X, Wang X, Zhang L, Qiang C, Chang S, Ren W, Li S, Yang Y, Tong D, Chen C, Li Z, Song T, Zhi K, Huang C. 2014. IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma. Oncotarget 5:2562-2574.